Lenalidomide has activity in<unk> - syndrome and is FDA approved for red blood cell (RBC) transfusion-dependent anemia due to low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS) associated with<unk> <unk>  deletion with or without additional cytogenetic abnormalities. There are several possible mechanisms that link the haploinsufficiency molecular lesions with lenalidomide sensitivity.
Chromosome 5q deletion syndrome
Chromosomal deletion syndrome
13q deletion syndrome
22q11.2 distal deletion syndrome
22q11.2 duplication syndrome
22q13 deletion syndrome
1q21.1 deletion syndrome
2q37 deletion syndrome